Rogers Corporation - SIC # 3671 - ELECTRON TUBES

Ticker Exchange SIC # Website Latest Ticker
ROG New York 3671 www.rogerscorp.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rogers Corporation

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories - Oct 27th, 2026 12:00 am
Rogers (ROG) to report earnings tomorrow: here is what to expect - Oct 25th, 2026 10:54 pm
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer - Oct 25th, 2026 9:30 am
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) - Oct 23rd, 2026 11:30 am
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […] - Oct 21st, 2026 11:00 pm
Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026 - Oct 21st, 2026 6:00 am
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio - Oct 18th, 2026 11:00 pm
FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) - Oct 15th, 2026 11:00 pm
Rogers Corporation Schedules Third Quarter 2026 Earnings Call for October 27 - Oct 13th, 2026 2:05 pm
Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases - Oct 13th, 2026 1:00 am
Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss - Oct 10th, 2026 3:40 pm
FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer - Oct 8th, 2026 11:00 pm
Rogers Targets $1.5B Sales by 2030 on AI Data Center, Battery Growth - Oct 3rd, 2026 2:02 am
Rogers Corp. (ROG) Moves 10.7% Higher: Will This Strength Last? - Oct 1st, 2026 4:01 am
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions - Oct 1st, 2026 12:00 am
Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine - Sep 30th, 2026 11:00 pm
Rogers Stock Surges 11% After Investor Day. Here’s Why - Sep 30th, 2026 8:00 pm
Rogers (ROG) Shares Skyrocket, What You Need To Know - Sep 30th, 2026 4:05 pm
Rogers Corporation Provides 2030 Financial Targets at 2026 Investor Day - Sep 30th, 2026 2:05 pm
Rogers Corporation to Host Investor Day on September 30, 2026 - Sep 30th, 2026 4:55 am